Reuters logo
BRIEF-Nuvo Pharmaceuticals says European ankle sprain study with Pennsaid 2 pct failed to meet primary endpoint
May 15, 2017 / 11:59 AM / 4 months ago

BRIEF-Nuvo Pharmaceuticals says European ankle sprain study with Pennsaid 2 pct failed to meet primary endpoint

May 15 (Reuters) - Nuvo Pharmaceuticals Inc

* Nuvo Pharmaceuticals Inc announces topline results from European ankle sprain study with Pennsaid 2 pct

* Nuvo Pharmaceuticals Inc - trial had failed to meet its primary endpoint

* Nuvo Pharmaceuticals - will continue to assess opportunities available to pursue marketing authorizations for Pennsaid 2 pct in Canada, Australia and E.U.

* Nuvo Pharmaceuticals - will be reviewing trial results in with its scientific advisors and regulatory consultants to determine what its next steps should be Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below